COSCIENS Biopharma Inc's fundamentals are relatively very healthy, Its valuation is considered fairly valued, Institutional ownership is very high.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
COSCIENS Biopharma Inc's Score
Industry at a Glance
Industry Ranking
276 / 689
Overall Ranking
423 / 4737
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
COSCIENS Biopharma Inc Highlights
StrengthsRisks
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.98% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.59M.
Fairly Valued
The company’s latest is -0.42, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 331.27K shares, decreasing 2.04% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.11.
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Ticker SymbolCSCI
CompanyCOSCIENS Biopharma Inc
CEOMs. Anna Biehn
Websitehttps://www.cosciensbio.com/
FAQs
What is the current price of COSCIENS Biopharma Inc (CSCI)?
The current price of COSCIENS Biopharma Inc (CSCI) is 2.720.
What is the symbol of COSCIENS Biopharma Inc?
The ticker symbol of COSCIENS Biopharma Inc is CSCI.
What is the 52-week high of COSCIENS Biopharma Inc?
The 52-week high of COSCIENS Biopharma Inc is 6.460.
What is the 52-week low of COSCIENS Biopharma Inc?
The 52-week low of COSCIENS Biopharma Inc is 2.900.
What is the market capitalization of COSCIENS Biopharma Inc?
The market capitalization of COSCIENS Biopharma Inc is 8.64M.
What is the net income of COSCIENS Biopharma Inc?
The net income of COSCIENS Biopharma Inc is -15.31M.
Is COSCIENS Biopharma Inc (CSCI) currently rated as Buy, Hold, or Sell?
According to analysts, COSCIENS Biopharma Inc (CSCI) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of COSCIENS Biopharma Inc (CSCI)?
The Earnings Per Share (EPS TTM) of COSCIENS Biopharma Inc (CSCI) is -6.544.